CALR and myeloproliferative neoplasm: In one study [59], CALR testing in patients with spleen height ≥16 cm, platelet count >200 × 109/L, and no JAK2V617F mutation, yielded a positive predictive value of 56% and negative predictive value of 99% for MPN.